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Drug assessment in the 
Ebola virus disease 
epidemic in west Africa 
In their Personal View, Simone 
Lanini and colleagues1
 
argued that 
an adaptive randomised controlled 
trial (RCT) is the optimum solution to 
assess experimental therapeutics for 
Ebola virus disease and that non-RCTs 
are “profoundly unethical”. 
Lanini and colleagues distinguished 
study designs of experimental 
agents as randomised versus non-
randomised studies, including within 
the latter anecdotal experiences and 
compassionate use. It is irrational 
to make no distinction between 
phase 2 clinical trials and compassionate 
treatment. Studies by our groups, which 
were also cited by Lanini and colleagues, 
are fully regulated phase 2 clinical trials 
with explicit study frameworks. 
Moreover, we studied interventions 
that have been approved by regulatory 
authorities for use in man and imple-
mented them only following full 
ethical review and approval. Clinical 
drug trials can be legitimately done 
only with the consent of individuals 
and communities. We worked with 
communities to facilitate open 
dialogue and partnership, which 
shows that RCTs would not have been 
accepted at the time the trials were 
initiated. 
In  1990,  recognising that 
traditional approaches to clinical 
trial processes were unnecessarily 
rigid and un suitable for study of HIV 
treatments, Byar and colleagues2 
concluded, in their paper design 
considerations for AIDS trials, that 
non-RCTs could be considered in the 
following situations. First, “there 
must be sufficient experience to 
ensure that the patients not receiving 
therapy will have a uniformly poor 
prognosis”. Second, “there must 
be no other treatment appropriate 
to use as a control”. Third, “the 
therapy must not be expected 
to have substantial side effects”. 
Fourth, “there must be a justiﬁ able 
expectation that the potential beneﬁ t 
to the patient will be suﬃ  ciently large 
to make interpretation of a non-RCT 
unambiguous”. Fifth, “the scientiﬁ c 
rationale for the treatment must be 
sufficiently strong that a positive 
result would be widely accepted”.
The Ebola epidemic clearly fulfils 
the ﬁ rst and second criteria, since the 
fatality is high.3,4
 
The third criterion 
was met for most of the strategies 
studied. Regarding criterion four, our 
approach was to triage treatments 
into those with no eﬀ ect that should 
be discarded quickly, from those with 
clear beneﬁ ts that should be rolled out 
immediately, and those with promise 
that needs to be assessed in a RCT, in 
which combination antivirals could be 
also studied.5
 
This strategy is also more 
acceptable to patients, physicians, and 
local communities. 
A debate on clinical trial design 
during humanitarian crises is needed, 
but it has to be based on an accurate 
characterisation of the events and 
issues. 
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 Ebola: Europe–Africa 
research collaborations
No one would disagree with Giuseppe 
Ippolito and colleagues1 about the need 
to strengthen Europe–Africa research 
collaborations for health threats such as 
Ebola. This imperative must, however, 
build upon the current landscape of 
partnerships for epidemic diseases 
research in Africa and elsewhere. 
The Europe–Africa clinical research 
response to Ebola has been impressive, 
and includes vaccine safety studies in 
west Africa,2,3 the encouraging results 
of the ring vaccination trial in Guinea 
coordinated by WHO,4 the first ever 
drug trial in Ebola undertaken by 
the favipiravir (JIKI) trial consortium 
(NCT02329054),5 the RAPIDE con-
sortium trials of brincidofovir 
(PACTR201411000939962) and TKM-
130803 (PACTR201501000997429), 
and the Ebola-Tx (NCT02342171) and 
Ebola-CP (ISRCTN13990511) trials of 
convalescent plasma. 
With the inclusion of diagnostic, 
virological, and anthropological 
research, Europe–Africa Ebola research 
collaborations have been prolific. 
These achievements, which should be 
celebrated, are partly the consequence 
of investments over the past 5 years 
in many of the areas highlighted by 
Ippolito and colleagues. To cite only 
a few, the International Severe Acute 
Respiratory and emerging Infections 
Consortium (ISARIC) has been striving 
to align existing networks since 2011, 
and has pioneered the development 
of pre-approved and adaptable 
For more on ISARIC see http://
www.isaric.org
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cancer, and chronic treatment with 
steroids or immunosuppressors for 
respiratory or autoimmune diseases 
aﬀ ect basal immune status, increasing 
the risk of infection and sepsis.2 Critical 
illness or aggressive surgery represent 
an  additional challenge for these 
patients because of the transient state 
of immunosuppression induced. 
Immunological assessment of these 
at-risk individuals (other than testing 
leukocyte counts in the blood) is not 
included in the routine exams they 
undergo in primary health centres or 
nursing homes. It is neither done when 
these patients are admitted to hospital 
or critical care units, nor when they are 
facing major surgery. Emergence of 
new technologies allows the status of 
both innate and adaptive immunity 
to be analysed at a reasonable cost. 
Examples of these technologies 
are assessment in the blood of the 
expression levels of selected immune-
related genes, such as HLA-DR, by 
real-time PCR3 or droplet digital PCR,4 
and quantification of interferons, 
cytokines, and chemokines with 
multiplex assays. These new tests 
could be complementary to con-
ventional ones, such as quantiﬁ cation 
of CD4 and CD8 T-cell counts in 
the blood, quantification in serum 
of immunoglobulin isotypes and 
complement factors (C3, C4, B),5 or 
the assessment of cellular immuno-
competence by the QuantiFERON test. 
Intensiﬁ cation of hygienic measures, 
more careful monitoring of clinical 
signs of infection, implementation 
of earlier microbiological testing, 
prophylaxis with antibiotics, or 
delaying programmed surgery to allow 
immunological recovery in patients 
receiving immunosuppressors are all 
potential measures that could help 
to prevent community-acquired or 
nosocomial sepsis in predisposed 
patients because of their compromised 
immunological status. The potential 
role of drugs such as interleukin 15, 
interleukin 7, or IMT504 to restore 
immunity and prevent sepsis in 
these patients is an exciting ﬁ eld of 
Preventing sepsis
As highlighted by Jonathan Cohen 
and colleagues in their Commission,1 
mortality remains high in severe forms 
of sepsis.1 The authors provided an 
extensive review of the key issues to 
be addressed in future research to 
develop better treatment strategies 
that can improve the present scenario. 
In our view, in the absence of eﬀ ective 
treatments, prevention of sepsis is 
the best way to diminish morbidity 
and mortality associated with this 
complication. Most patients with 
sepsis are elderly individuals with 
comorbidities.2 Immunosenescence, 
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syndrome-based protocols. ISARIC 
has African member networks and is 
active in building regional capacity and 
linkages. Affiliated with ISARIC, the 
European Union (EU)-funded Platform 
for European Preparedness Against 
(Re-)emerging Epidemics (PREPARE) is 
undertaking inter-epidemic syndrome-
based studies across Europe, and both 
ISARIC and PREPARE have begun 
to address ethical, administrative, 
regulatory, and legal bottlenecks 
to rapid research. To accelerate and 
coordinate funding of a rapid research 
response to outbreaks, a network of 
funders has established the Global 
Research Collaboration for Infectious 
Disease Preparedness (GloPID-R). The 
European and Developing Countries 
Clinical Trials Partnership, funded by 
the EU, provides substantial support 
for training and capacity development 
in Africa in the conduct of clinical 
trials. At the European country level, 
initiatives such as REACTing (REsearch 
and ACTion targeting emerging 
infectious diseases) and The Global 
Health Network (TGHN) have emerged 
to support research preparedness 
and capacity within low-income and 
middle-income countries. TGHN is 
providing free web-based courses 
to deliver research skills training to 
researchers in low-resource settings, 
with more than 40 000 of these being 
taken online in Africa so far. These 
many successes and ongoing initiatives 
should be the platforms from which we 
continue to strengthen Europe–Africa 
partnerships and help empower African 
researchers and institutions.
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